Alembic Pharmaceuticals Limited

rs,

te: 5th August, 2025 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 533573 To, The Manager, Listing Department,

INR 17.11

tance. Alembic Pharmaceuticals Ltd. Investor Presentation Q1 FY26 2 Quarterly Snapshot Revenue INR 17.11 Bn +10% YoY Key Highlights India Branded Business Achieved an 5% YoY growth, with quarterly reve

10%

Pharmaceuticals Ltd. Investor Presentation Q1 FY26 2 Quarterly Snapshot Revenue INR 17.11 Bn +10% YoY Key Highlights India Branded Business Achieved an 5% YoY growth, with quarterly revenues of

5%

terly Snapshot Revenue INR 17.11 Bn +10% YoY Key Highlights India Branded Business Achieved an 5% YoY growth, with quarterly revenues of INR 5.99 billion EBIDTA INR 2.88 Bn EBIDTA Margin ~17% +20

INR 5.99 billion

YoY Key Highlights India Branded Business Achieved an 5% YoY growth, with quarterly revenues of INR 5.99 billion EBIDTA INR 2.88 Bn EBIDTA Margin ~17% +20% YoY Reported a 13% YoY increase, driven by the ramp u

INR 2.88

ia Branded Business Achieved an 5% YoY growth, with quarterly revenues of INR 5.99 billion EBIDTA INR 2.88 Bn EBIDTA Margin ~17% +20% YoY Reported a 13% YoY increase, driven by the ramp up of key product l

17%

ed an 5% YoY growth, with quarterly revenues of INR 5.99 billion EBIDTA INR 2.88 Bn EBIDTA Margin ~17% +20% YoY Reported a 13% YoY increase, driven by the ramp up of key product launches and market

20%

5% YoY growth, with quarterly revenues of INR 5.99 billion EBIDTA INR 2.88 Bn EBIDTA Margin ~17% +20% YoY Reported a 13% YoY increase, driven by the ramp up of key product launches and market share

13%

quarterly revenues of INR 5.99 billion EBIDTA INR 2.88 Bn EBIDTA Margin ~17% +20% YoY Reported a 13% YoY increase, driven by the ramp up of key product launches and market share gains in select ther

8%

he ramp up of key product launches and market share gains in select therapies. US Generics R&D 8% of revenue +26% YoY Net Profit INR 1.55 Bn Net Profit Margin 9% +15% YoY Ex-US Generics Deliv

26%

y product launches and market share gains in select therapies. US Generics R&D 8% of revenue +26% YoY Net Profit INR 1.55 Bn Net Profit Margin 9% +15% YoY Ex-US Generics Delivered 21% YoY grow

INR 1.55

and market share gains in select therapies. US Generics R&D 8% of revenue +26% YoY Net Profit INR 1.55 Bn Net Profit Margin 9% +15% YoY Ex-US Generics Delivered 21% YoY growth in Q1, supported by gro

“Investor Presentation Q1 FY26 17 Robust infrastructure International Generics F1 - Panelav F2 - Panelav F3 - Karkhadi F4 - Jarod F5 - Karkhadi API API I & II – Panelav API III - Karkhadi Dosage Form Last USFDA Audit General Oral Solids July’24 Oncology Oral Solids Mar’24 Oncology Injectables Oct’24 General Injectables Ophthalmic Mar’23 General Oral Solids Nov’24 Various derma forms Mar’23 May’25* Mar’25 * API I & II : Initial Response to observations (FDA Form 483) is submitted.”

Established US front end

1

Established US front end

transition to direct marketing 2025 Indore facility Commissioned & Acquired Utility Therapeutics Limited 2023 Started commercializati on of products from Injectables and Oncology facilities 2022 Azithral ranked 16th highest selling brand. Aleor Dermaceuticals merged with Alembic Pharma Alembic Pharmaceuticals Ltd. Investor Presentation Q1 FY26 17 Robust infrastructure International Generics F1 - Panelav F2 - Panelav F3 - Karkhadi F4 - Jarod F5 - Karkhadi API API I & II – Panelav API III - Karkhadi Dosage Form Last USFDA Audit General Oral Solids July’24 Oncology Oral Solids Mar’24 Oncology Injectables Oct’24 General Injectables Ophthalmic Mar’23 General Oral Solids Nov’24 Various derma forms Mar’23 May’25* Mar’25 * API I & II : Initial Response to observations (FDA Form 483) is submitted. F2 - Panelav F3 - Karkhadi F4 - Jarod F5 - Karkhadi Alembic Pharmaceuticals Ltd. Investor Presentation Q1 FY26 18 Yearly Financials Revenue EBIDTA Net Profit 53.06 56.53 62.29 66.72 10.53 9.61 # 10.53